PQXDOD1: Defense Health Agency- Development of a Medical Device Utilizing an EEG-Based Algorithm for the Objective Quantification of Pain

Sponsor
PainQx, Inc (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05215184
Collaborator
United States Department of Defense (U.S. Fed)
350
5
14.5
70
4.8

Study Details

Study Description

Brief Summary

PainQx, with the support of the Department of Defense (Contract #W81XWH-21-C-0034), is conducting a study to collect electroencephalography (EEG) data from people with chronic pain in order to develop algorithms than will objectively assess the pain a person is experiencing. EEG is a monitoring method that records electrical activity in the brain. If enrolled in the study, subjects will be asked to answer a series of questions regarding their level of chronic pain, level of functionality, symptoms, behavioral health information, and medications, and subsequently have a 15 minute, non-invasive EEG recording taken by placing electrodes along the scalp. Through participation, chronic pain subjects will provide data needed to further develop this technology.

Condition or Disease Intervention/Treatment Phase
  • Device: Zeto WR19 EEG Recording

Study Design

Study Type:
Observational
Anticipated Enrollment :
350 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Defense Health Agency- Development of a Medical Device Utilizing an EEG-Based Algorithm for the Objective Quantification of Pain
Actual Study Start Date :
Sep 15, 2021
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Chronic Pain Patients

Device: Zeto WR19 EEG Recording
15 minutes of EEG recording to be obtained from eligible participants

Healthy Controls

Device: Zeto WR19 EEG Recording
15 minutes of EEG recording to be obtained from eligible participants

Outcome Measures

Primary Outcome Measures

  1. Pearsons Correlation between ALGOS derived pain biomarker and patient reported Defense and Veterans Pain Rating Scale (0-10) [Data analysis occurs within 3 months of study completion]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male and female chronic pain patients

  • Patients between the ages of 18-85 years

  • Patients exhibiting the presence of symptoms in excess of 3 months duration

  • Patients suffering from neuropathic (e.g., lower back pain), osteoarthritis, or muscular skeletal pain

  • Patients with evidence of pathology related to the painful condition on which diagnosis was made (e.g., results of imaging or diagnostic pain code)

  • Patients with NRS pain scores across the full range (0-10) at the time of testing

Exclusion Criteria:
  • • Patients with medically diagnosed psychotic illness, such as Schizophrenia

  • Patients with medically diagnosed drug or alcohol dependence in the past 12 months

  • Patients with a medical history of head injury with loss of consciousness and amnesia (within the last 2 years)

  • Patients with skull abnormalities that preclude the proper placement of the electrodes for EEG data acquisition

  • Patients who have a spinal cord stimulator, neurological implants, deep brain stimulators, or other pain related implantable devices such as an intrathecal drug pump

  • Patients for whom the source of pain at the time of the evaluation is associated with: neurological disorders (multiple sclerosis, Parkinson, dementia), diabetes, migraines, or those with reflex / sympathetic dystrophy disorder/complex regional pain syndrome, fibromyalgia, or visceral pain

o Note: This does not exclude patients who suffer from these disorders if the current source of pain is not due to the disorder. For example, patients with diabetes are NOT excluded, but patients whose pain at the time of the evaluation is a result of diabetic neuropathy are excluded. Similarly, patients with a history of migraines but for whom a migraine is not the current source of pain at the time of the evaluation are NOT excluded.

  • Patients with cancer

o Note: This does not exclude patients who have been in complete remission for more than two years

  • Patients on workers compensation or disability or have other circumstances which may cause/incentive them to misreport their pain

  • Patient on gabapentin or pregabalin (within the last month)

  • Patients on experimental drugs (i.e. participating in drug trial), use off-label drugs, or are on unapproved dosages

  • Patients who have a history of seizures (within the past 3 months)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Panorama Orthopedics & Spine Center Golden Colorado United States 80401
2 Indiana Spine Group Carmel Indiana United States 46032
3 Comprehensive Spine and Pain Center of New York New York New York United States 10017
4 Weill Cornell Medicine New York New York United States 10065
5 Center for Interventional Pain and Spine Lancaster Pennsylvania United States 17601

Sponsors and Collaborators

  • PainQx, Inc
  • United States Department of Defense

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
PainQx, Inc
ClinicalTrials.gov Identifier:
NCT05215184
Other Study ID Numbers:
  • Pro00054666
First Posted:
Jan 31, 2022
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022